EANS 2026. Listen to an overview here: audio file (SV) audio file (EN) Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor [...]
Double Bond Pharmaceutical will conduct an upcoming post-marketing study of Temodex to examine real-world survival outcomes in clinical practice. The results will help validate the SI-053 program. Listen to an overview here: audio file (SV) audio file (EN) Contact information Full Company [...]
Glioblastoma (GBM) remains the most aggressive and treatment-resistant primary brain tumor, with median overall survival rarely exceeding 15–20 months despite advances in surgery, imaging, and systemic therapy. The key barriers are persistent: incomplete resection, limited drug penetration across the blood–brain barrier (BBB), and a microenvironment that suppresses immune activity while promoting recurrence. In [...]
This document has been prepared by Double Bond Pharmaceutical for the purpose of summarising current scientific literature and providing a short assessment of the challenges and therapeutic opportunities in glioblastoma treatment. 13th August 2025. Glioblastomas' significant heterogeneity complicates diagnosis in an era of increasing reliance on genotyping, as traditional biopsies may provide an [...]
According to the results of open, controlled, retro prospective, comparative, randomized clinical trial found an increase in the efficacy of the combined treatment of malignant brain tumors in the application of intraoperative local chemotherapy drug (LHT) temodex. In particular, the median survival of patients with Grade III–IV tumors in the supratentorial localization background [...]
The assessment of the clinical progression of the postoperative period in patients with neuroepithelial brain tumors when using intraoperative local chemotherapy (iLCT) with Temodex, which is an anticancer medicinal product of the active substance of temozolomide immobilized on highly substituted dextran phosphate. Clinical manifestations and features of the early postoperative period were analyzed depending [...]
Glioma is the most common brain malignancy. Standard first-line therapy for glioma includes surgery, radiotherapy and systemic administration of temozolomide. However, temozolomide does not reach the brain in sufficient doses when administered orally and has poor efficiency in more than half of the patients. Strategies to improve the treatment of glial malignancies are [...]
In recent years, it has been increasingly recognized that tumor growth relies not only on support from the surrounding microenvironment but also on the tumors capacity to adapt to - and actively manipulate - its niche. While targeting angiogenesis and modulating the local immune environment have been explored as therapeutic approaches, these strategies [...]
Temodex prolongs survival in glioma patients 2019 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow [...]
Our expert view on Drug Delivery 2017 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow [...]
